Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 8/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094713 | 0.90 | QPCT (0.42) | QPCTALDH1A1LMNAHPGDAR | |
| SCHEMBL6096236 | 0.84 | ALDH1A1 (0.54) | QPCTALDH1A1LMNACYP2C9HPGD | |
| SCHEMBL6096595 | 0.82 | AR (0.53) | ALDH1A1LMNACYP2C9HPGDAR | |
| SCHEMBL6095163 | 0.81 | MEN1 (0.52) | QPCTALDH1A1LMNACYP2C9HPGD | |
| SCHEMBL6098243 | 0.80 | LMNA (0.56) | LMNACYP2C9HPGDARGAA | |
| SCHEMBL6095168 | 0.78 | LMNA (0.48) | LMNACYP2C9HPGDAR | |
| SCHEMBL6097934 | 0.77 | KDM4E (0.54) | QPCTALDH1A1LMNACYP2C9HPGD | |
| SCHEMBL6096023 | 0.77 | SMN1; SMN2 (0.56) | QPCTALDH1A1LMNAGAAMAPT | |
| SCHEMBL6097863 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNACYP2C9HPGDAR | |
| SCHEMBL6097519 | 0.76 | LMNA (0.50) | ALDH1A1LMNACYP2C9HPGDAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115745-B2 | Benzyl urea and thiourea derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-10-03 | — | — | US | claimed |
| EP-1597233-A1 | BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072043-A1 | BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-26 | — | — | WO | claimed |
| US-7115745-B2 | Benzyl urea and thiourea derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1597233-A1 | BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050107427-A1 | Benzyl urea and thiourea derivatives | DU DANIEL Y (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2004072043-A1 | BENZYL UREA AND THIOUREA DERIVATIVES USEFUL AS ANDROGEN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107427-A1 | Benzyl urea and thiourea derivatives | BRDT, TAS2R8, FSHR | QPCT 749/4885ALDH1A1 1968/4885LMNA 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.